Oncotherapeutics

Executive Summary

Oncotherapeutics is a strategic Contract Research Organization (CRO) uniquely focused on community-based Hematology & Oncology research sites across the United States. Founded in 2009 and based in Los Angeles, the company operates multiple clinical trials that leverage real-world data and outcomes to improve the clinical utility of cancer therapies. Unlike traditional CROs centered on academic institutions, Oncotherapeutics' community site network enables faster patient enrollment, more diverse populations, and practical insights into standard-of-care settings. The company targets Phase 1 oncology trials for small molecules, positioning itself as a key partner for biopharma firms seeking efficient and representative clinical development. With a lean operation and specialized niche, Oncotherapeutics is well-placed to capture growing demand for decentralized and community-based research. However, its lack of proprietary assets and dependence on external trial sponsors introduces revenue variability and competitive pressures from larger CROs.

Upcoming Catalysts (preview)

• Q3 2026Announcement of major new contract with top-20 pharma for phase 1 oncology trial60% success
• Q4 2026Expansion into 5 new community oncology sites in the Southeastern US75% success
• Q2 2026Publication of real-world outcomes data from completed trial demonstrating improved enrollment diversity80% success